ReviewSeminars in immunopathology2019
Osteoclastic microRNAs and their translational potential in skeletal diseases.
Review in Seminars in immunopathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Pyroptosis in bone loss.Apoptosis : an international journal on programmed cell death · 2023Review
- Adenovirus-associated anti-miRNA-214 regulates bone metabolism and prevents local osteoporosis in rats.Frontiers in bioengineering and biotechnology · 2023Article
- Osteoporosis pathogenesis and treatment: existing and emerging avenues.Cellular & molecular biology letters · 2022Review
- Regulation of osteoclast-mediated bone resorption by microRNA.Cellular and molecular life sciences : CMLS · 2022Review
- Effect of alendronate on the femoral metaphyseal defect under carbamazepine in ovariectomized rats.Journal of orthopaedic surgery and research · 2021Article
- Exosomes Derived from Pancreatic Cancer Cells Induce Osteoclast Differentiation Through the miR125a-5p/TNFRSF1B Pathway.OncoTargets and therapy · 2021Article
- The roles of miRNA, lncRNA and circRNA in the development of osteoporosis.Biological research · 2020Review
- miR-128 plays a critical role in murine osteoclastogenesis and estrogen deficiency-induced bone loss.Theranostics · 2020Article
- Periprosthetic Osteolysis: Mechanisms, Prevention and Treatment.Journal of clinical medicine · 2019Review
- Osteoimmunology: entwined regulation of integrated systems.Seminars in immunopathology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Skeleton undergoes constant remodeling process to maintain healthy bone mass. However, in pathological conditions, bone remodeling is deregulated, resulting in unbalanced bone resorption and formation. Abnormal osteoclast formation and activation play a key role in osteolysis, such as in rheumatoid arthritis and osteoporosis. As potential therapeutic targets or biomarkers, miRNAs have gained rapidly growing research and clinical attention. miRNA-based therapeutics is recently entering a new era for disease treatment. Such progress is emerging in treatment of skeletal diseases. In this review, we discuss miRNA biogenesis, advances in the strategies for miRNA target identification, important miRNAs involved in osteoclastogenesis and disease models, their regulated mechanisms, and translational potential and challenges in bone homeostasis and related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.